126 related articles for article (PubMed ID: 35227076)
1. Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer.
Zhong W; Yi J; Wu H; Zou X; Feng J; Huang X; Li S; Wang X
Future Oncol; 2022 May; 18(14):1745-1756. PubMed ID: 35227076
[No Abstract] [Full Text] [Related]
2. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V
J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859
[TBL] [Abstract][Full Text] [Related]
5. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor expression is useful to predict the therapeutic effect in HER2-positive breast carcinoma.
Akashi M; Yamaguchi R; Kusano H; Ogasawara S; Abe E; Obara H; Yamaguchi M; Akiba J; Kakuma T; Tanaka M; Akagi Y; Yano H
Breast Cancer Res Treat; 2020 Nov; 184(2):277-285. PubMed ID: 32770457
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
9. Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients.
Li N; Wu J; Qi X; Yang Q; Liu R; Yang Y; Li C; Huang M; Lin M; Wang C; Cha Z; Hou X; Luo L; Ge F; Chen W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10109-10117. PubMed ID: 37264265
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer.
You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
[TBL] [Abstract][Full Text] [Related]
11. Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study.
Jinna ND; Van Alsten S; Rida P; Seewaldt VL; Troester MA
Breast Cancer Res Treat; 2023 Sep; 201(2):171-181. PubMed ID: 37438515
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
He J; Peng R; Yuan Z; Wang S; Peng J; Lin G; Jiang X; Qin T
Med Oncol; 2012 Jun; 29(2):406-10. PubMed ID: 21264529
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
[TBL] [Abstract][Full Text] [Related]
15. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
16. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.
Jiang HS; Kuang XY; Sun WL; Xu Y; Zheng YZ; Liu YR; Lang GT; Qiao F; Hu X; Shao ZM
Oncotarget; 2016 Jul; 7(27):41285-41293. PubMed ID: 27285752
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
Niméus E; Folkesson E; Nodin B; Hartman L; Klintman M
Anticancer Res; 2017 Dec; 37(12):6845-6853. PubMed ID: 29187464
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]